The story of Sildenafil presents a complex picture for those considering investment. While the initial introduction generated substantial gains, the expiration of its patent opened the door to cheaper alternatives, dramatically reducing sales. This poses a particular challenge for firms depending on related blockbuster products, suggesting that a c

The story of Viagra, and its parent company copyright, presents a challenging case study for investors. At first a blockbuster drug, generating billions in income, its intellectual property lapse created a flood of generic competition , significantly eroding its dominance. While some firms may try to capitalize on related treatments , the existing